METHODS: We included 172 DN and 38 nevus-associated MIS from our institutional archive. PRAME positive expression was defined as nuclear staining in at least 75% of melanocytes. In addition, relevant studies from PubMed and Web of Science were incorporated into a meta-analysis using the random-effects model to assess PRAME expression in MIS and DN.
RESULTS: Our institutional data revealed that 71.1% of nevus-associated MIS cases exhibited positive PRAME expression in the MIS components, whereas all DN components were negative for PRAME. 5.7% of cases diagnosed as DN in our cohort demonstrated diffuse positivity for PRAME. Notably, MIS associated with DN displaying epidermal and dermal components displayed a higher likelihood of PRAME positivity compared to those arising on a background of DN with solely epidermal (junctional) components (84% vs. 46%, p = 0.024). The meta-analysis indicated that the pooled PRAME positivity in MIS and DN was 54.5% and 1.9%, respectively.
CONCLUSIONS: PRAME is a valuable immunohistochemical marker for differentiating MIS from DN, particularly in the context of nevus-associated MIS.
方法:我们从机构档案中包括了172个DN和38个痣相关的MIS。PRAME阳性表达被定义为在至少75%的黑素细胞中的核染色。此外,使用随机效应模型将PubMed和WebofScience的相关研究纳入meta分析,以评估PRAME在MIS和DN中的表达.
结果:我们的机构数据显示,71.1%的痣相关MIS病例在MIS组件中表现出PRAME阳性表达,而所有DN成分的PRAME均为阴性。在我们的队列中,有5.7%的被诊断为DN的病例表现出PRAME的弥漫性阳性。值得注意的是,与显示表皮和真皮成分的DN相关的MIS与仅具有表皮(连接)成分的DN背景下出现的MIS相比,PRAME阳性的可能性更高(84%vs.46%,p=0.024)。荟萃分析表明,MIS和DN的合并PRAME阳性率分别为54.5%和1.9%,分别。
结论:PRAME是区分MIS和DN的有价值的免疫组织化学标记,特别是在痣相关MIS的背景下。